HumuloneCAS# 26472-41-3 |
2D Structure
- Humulon
Catalog No.:BCC8186
CAS No.:23510-81-8
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
Cas No. | 26472-41-3 | SDF | Download SDF |
PubChem ID | 72625 | Appearance | Powder |
Formula | C21H30O5 | M.Wt | 362.45 |
Type of Compound | Miscellaneous | Storage | Desiccate at -20°C |
Synonyms | Humulon,alpha-Humulon | ||
Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
Chemical Name | (6S)-3,5,6-trihydroxy-2-(3-methylbutanoyl)-4,6-bis(3-methylbut-2-enyl)cyclohexa-2,4-dien-1-one | ||
SMILES | CC(C)CC(=O)C1=C(C(=C(C(C1=O)(CC=C(C)C)O)O)CC=C(C)C)O | ||
Standard InChIKey | VMSLCPKYRPDHLN-NRFANRHFSA-N | ||
Standard InChI | InChI=1S/C21H30O5/c1-12(2)7-8-15-18(23)17(16(22)11-14(5)6)20(25)21(26,19(15)24)10-9-13(3)4/h7,9,14,23-24,26H,8,10-11H2,1-6H3/t21-/m0/s1 | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | 1. Humulone has antioxidant activity. 2. Humulone is an antispasmodic agent. 3. Humulone has antiviral and antibacterial activities. 4. Humulone, a bone resorption inhibitor, induces apoptosis may via its antioxidative activity in the premyocytic leukemia cell line HL-60 between 1 and 100 micrograms/ml. 5. Humulone is a potent angiogenic inhibitor, can inhibit cyclooxygenase-2 and may be a novel powerful tool for the therapy of various angiogenic diseases involving solid tumor growth and metastasis. |
Targets | IL Receptor | AP-1 | COX | p65 | NF-kB | IkB | VEGFR | Antifection | IKK |
Humulone Dilution Calculator
Humulone Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 2.759 mL | 13.795 mL | 27.59 mL | 55.18 mL | 68.975 mL |
5 mM | 0.5518 mL | 2.759 mL | 5.518 mL | 11.036 mL | 13.795 mL |
10 mM | 0.2759 mL | 1.3795 mL | 2.759 mL | 5.518 mL | 6.8975 mL |
50 mM | 0.0552 mL | 0.2759 mL | 0.5518 mL | 1.1036 mL | 1.3795 mL |
100 mM | 0.0276 mL | 0.138 mL | 0.2759 mL | 0.5518 mL | 0.6898 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- 26-Deoxyactein
Catalog No.:BCN8076
CAS No.:264624-38-6
- MRS 1754
Catalog No.:BCC7473
CAS No.:264622-58-4
- MRS 1706
Catalog No.:BCC7120
CAS No.:264622-53-9
- SSR 146977 hydrochloride
Catalog No.:BCC7635
CAS No.:264618-38-4
- PR-619
Catalog No.:BCC3627
CAS No.:2645-32-1
- Bz-Arg-OEt.HCl
Catalog No.:BCC2686
CAS No.:2645-08-1
- Methyl 2,2-dithienylglycolate
Catalog No.:BCC9034
CAS No.:26447-85-8
- Oxypeucedanin hydrate
Catalog No.:BCN2698
CAS No.:2643-85-8
- 6',7'-Dihydroxybergamottin
Catalog No.:BCN5142
CAS No.:264234-05-1
- Methyl 5-{2-[(tert-butylamino)carbothioyl]carbohydrazonoyl}-1-(2,4-difluorophenyl)-1H-pyrazole-4-carboxylate
Catalog No.:BCC7906
CAS No.:264233-05-8
- SB 415286
Catalog No.:BCC3651
CAS No.:264218-23-7
- Z-Orn-OH
Catalog No.:BCC2757
CAS No.:2640-58-6
- Catharanthine Tartrate
Catalog No.:BCN2462
CAS No.:2648-21-5
- 6-Deoxyisojacareubin
Catalog No.:BCN7723
CAS No.:26486-92-0
- Cyclo(D-Phe-L-Pro)
Catalog No.:BCN4011
CAS No.:26488-24-4
- Clovanediol
Catalog No.:BCN5143
CAS No.:2649-64-1
- Clovanediol diacetate
Catalog No.:BCN5144
CAS No.:2649-68-5
- Nandrolone laurate
Catalog No.:BCC9088
CAS No.:26490-31-3
- Z-Gln-OH
Catalog No.:BCC2783
CAS No.:2650-64-8
- Methyleugenolglycol
Catalog No.:BCN6562
CAS No.:26509-45-5
- N-[Bis(methylthio)methylene]- p-toluenesulfonamide
Catalog No.:BCC9069
CAS No.:2651-15-2
- Taiwanhomoflavone A
Catalog No.:BCN6853
CAS No.:265120-00-1
- Fosaprepitant dimeglumine salt
Catalog No.:BCC4954
CAS No.:265121-04-8
- GW 7647
Catalog No.:BCC7150
CAS No.:265129-71-3
Humulone suppresses replication of respiratory syncytial virus and release of IL-8 and RANTES in normal human nasal epithelial cells.[Pubmed:23381605]
Med Mol Morphol. 2013 Dec;46(4):203-9.
Respiratory syncytial virus (RSV) is the major infectious agent causing serious respiratory tract inflammation in infants and young children. However, an effective vaccine and anti-viral therapy for RSV infection have not yet been developed. Hop-derived bitter acids have potent pharmacological effects on inflammation. Therefore, we investigated the effects of Humulone, which is the main constituent of hop bitter acids, on the replication of RSV and release of the proinflammatory cytokine IL-8 and chemokine RANTES in RSV-infected human nasal epithelial cells (HNECs). We found that Humulone prevented the expression of RSV/G-protein, formation of virus filaments and release of IL-8 and RANTES in a dose-dependent manner in RSV-infected HNECs. These findings suggest that Humulone has protective effects against the replication of RSV, the virus assembly and the inflammatory responses in HNECs and that it is a useful biological product for the prevention and therapy for RSV infection.
Humulone inhibits phorbol ester-induced COX-2 expression in mouse skin by blocking activation of NF-kappaB and AP-1: IkappaB kinase and c-Jun-N-terminal kinase as respective potential upstream targets.[Pubmed:17372274]
Carcinogenesis. 2007 Jul;28(7):1491-8.
Humulone, a bitter acid derived from hop (Humulus lupulus L.), possesses antioxidative, anti-inflammatory and other biologically active activities. Although Humulone has been reported to inhibit chemically induced mouse skin tumor promotion, the underlying mechanisms are yet to be elucidated. Since an inappropriate over-expression of cyclooxygenase-2 (COX-2) is implicated in carcinogenesis, we investigated effects of Humulone on COX-2 expression in mouse skin stimulated with the tumor promoter 12-O-tetradecanoylphorbol-13-acetate (TPA). Topical application of Humulone (10 mumol) significantly inhibited TPA-induced epidermal COX-2 expression. Humulone also diminished TPA-induced DNA binding of nuclear factor-kappaB (NF-kappaB) and activator protein-1 (AP-1). Pre-treatment with Humulone attenuated TPA-induced phosphorylation of p65 and nuclear translocation of NF-kappaB subunit proteins. Humulone blunted TPA-induced activation of inhibitory kappaB (IkappaB) kinase (IKK) in mouse skin, which accounts for its suppression of phosphorylation and subsequent degradation of IkappaBalpha. An in vitro kinase assay revealed that Humulone could directly inhibit the catalytic activity of IKKbeta. Humulone suppressed the activation of mitogen-activated protein kinases (MAPKs) in TPA-treated mouse skin. The roles of extracellular signal-regulated protein kinase-1/2 and p38 MAPK in TPA-induced activation of NF-kappaB in mouse skin had been defined in our previous studies. The present study revealed that topical application of SP600125, a pharmacological inhibitor of c-Jun-N-terminal kinase (JNK), abrogated the activation of AP-1 and the expression of COX-2 in TPA-treated mouse skin. Taken together, Humulone suppressed TPA-induced activation of NF-kappaB and AP-1 and subsequent expression of COX-2 by blocking upstream kinases IKK and JNK, respectively, which may account for its antitumor-promoting effects on mouse skin carcinogenesis.
Inhibition of angiogenesis by humulone, a bitter acid from beer hop.[Pubmed:11708802]
Biochem Biophys Res Commun. 2001 Nov 23;289(1):220-4.
On the basis of our previous finding that Humulone, a bitter acid from beer hop extract, was a potent inhibitor of bone resorption and inhibited the catalytic activity of cyclooxygenase-2 (COX-2) and more potently the transcription of the COX-2 gene, we examined the effect of Humulone on angiogenesis, using chick embryo chorioallantoic membranes (CAMs) and vascular endothelial and tumor cells. Humulone significantly prevented in vivo angiogenesis in CAM in a dose-dependent manner with an ED(50) of 1.5 microg/CAM. Humulone also inhibited in vitro tube formation of vascular endothelial cells. Moreover, it suppressed the proliferation of endothelial cells and the production of vascular endothelial growth factor (VEGF), an angiogenic growth factor, in endothelial and tumor cells. Thus, Humulone is a potent angiogenic inhibitor, and may be a novel powerful tool for the therapy of various angiogenic diseases involving solid tumor growth and metastasis.
Induction of differentiation of myelogenous leukemia cells by humulone, a bitter in the hop.[Pubmed:9680110]
Leuk Res. 1998 Jul;22(7):605-10.
The active form of vitamin D, 1alpha,25-dihydroxyvitamin D3 (VD3), inhibits proliferation and induces differentiation of myelomonocytic leukemia cells, but its clinical use is limited by the adverse effect of hypercalcemia. VD3 mobilizes calcium stores from bone by inducing the dissolution of bone mineral and matrix. We have recently found that Humulone, a bitter in the hop extract for beer brewing, effectively inhibits bone resorption. In this study we examined the effect of Humulone on the differentiation of human myelogenous leukemia cells. Humulone alone inhibited the growth of monoblastic leukemia U937 cells while only slightly increasing differentiation markers such as nitroblue tetrazolium (NBT)-reducing and lysozyme activities. Humulone effectively enhanced the differentiation-inducing action of VD3. Other myelomonocytic leukemia cells were induced to differentiate by VD3 and this was also enhanced by Humulone. Since Humulone is a less-toxic inhibitor of bone resorption, the combination of Humulone and VD3 may be useful in differentiation therapy of myelomonocytic leukemia.